DH earnings analysis
What we found in DH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or MD&A, so quarterly financial trends and reported GAAP metrics cannot be independently assessed from the filing text provided. The principal new disclosure is a material Nasdaq continued-listing risk: the stock must regain a $1.00 bid price by December 15, 2026 after 30 consecutive business days below the threshold. Disclosure controls were effective as of June 30, 2026, and no material internal-control changes were identified during the quarter.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was recorded, processed, summarized, and reported on time.
- No material ICFR changes
- The filing reports no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq delisting compliance risk
- The company received a Nasdaq notice after its Class A common stock closed below the $1.00 minimum bid-price requirement for 30 consecutive business days ended June 17, 2026. It has until December 15, 2026, or 180 calendar days from the notice, to regain compliance; failure could lead to delisting, lower liquidity, and reduced access to capital.
What they said about what is next.
The supplied 10-Q text does not include quantitative revenue or EPS guidance. Numeric outlook was provided separately in the August 10, 2026 earnings release, not in the supplied filing excerpt.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 7, 2026
- Definitive Healthcare's Q1 2026 results showed a revenue of $55.9 million, beating estimates, and an EPS of $0.06, significantly surpassing expectations. Despite these top-line gains, the company reported a substantial…
- 10-K · February 26, 2026
- Definitive Healthcare positions itself as a SaaS healthcare commercial intelligence leader with a proprietary dataset and AI layer, serving ~2,330 customers as of December 31, 2025 across three end markets (Life…
- 10-K · February 27, 2025
- Definitive Healthcare positions itself as a SaaS healthcare commercial intelligence leader with a proprietary dataset and A.I. layer built over more than a decade; the company reported approximately 2,500 customers as…
- 10-Q · August 5, 2024
- Definitive Healthcare reported Q2 revenue of $63.737M, up from $60.957M a year earlier (+$2.78M, +4.6%), with gross margin roughly stable at 79.2%. The quarter included a $363.641M goodwill impairment that produced a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever